Several other recent studies provided evidence for at least four additional molecular subsets associated with poor prognosis: c-MYC-driven (MD)-DLBCL [119], stromal-II signature-subtype DLBCL [85], CDKN2A/2B (9p21)-deletion signature subtype DLBCL [120] and RCOR1-(TRAF3)-deletion signature subtype DLBCL [121]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.